Alex Vo
Overview
Explore the profile of Alex Vo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
212
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Good S, Luo S, Lin K, Vo A, Agrawal N, Sommadossi J
Antiviral Res
. 2025 Mar;
237:106137.
PMID: 40054502
Bemnifosbuvir (BEM), the orally available hemisulfate salt of the double prodrug of a guanosine nucleotide analog, is a potent, selective, and pan-genotypic inhibitor of HCV nonstructural protein 5B, an RNA-dependent...
2.
Rahman M, Tseng T, Pokojovy M, McCaffrey P, Walser E, Moen S, et al.
Diagnostics (Basel)
. 2024 Aug;
14(16).
PMID: 39202188
The class activation map (CAM) represents the neural-network-derived region of interest, which can help clarify the mechanism of the convolutional neural network's determination of any class of interest. In medical...
3.
Sun H, Cardinal K, Wienkers L, Chin A, Kumar V, Neace C, et al.
Cancer Chemother Pharmacol
. 2022 Apr;
89(6):737-750.
PMID: 35435471
Purpose: Tucatinib, a small molecule for the treatment of metastatic HER2-positive breast cancer, was extensively metabolized in humans to multiple oxidative metabolites. To fully understand the elimination and biotransformation pathways...
4.
Borges V, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, et al.
JAMA Oncol
. 2018 Jun;
4(9):1214-1220.
PMID: 29955792
Importance: Treatment options for patients with disease progression after treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited. Tucatinib is an oral, potent, human epidermal growth factor receptor 2...
5.
Murthy R, Borges V, Conlin A, Chaves J, Chamberlain M, Gray T, et al.
Lancet Oncol
. 2018 May;
19(7):880-888.
PMID: 29804905
Background: Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the potential to provide a well tolerated new treatment option for patients whose disease has progressed on...
6.
Gilbert K, Joseph R, Vo A, Patel T, Chaudhry S, Nguyen U, et al.
J Oral Microbiol
. 2014 Nov;
6.
PMID: 25405004
Background And Objectives: Mutans streptococci (MS) are one of the major microbiological determinants of dental caries. The objectives of this study are to identify distinct MS and non-MS streptococci strains...
7.
Bowles D, Senzer N, Hausman D, Peterson S, Vo A, Walker L, et al.
Invest New Drugs
. 2014 Jun;
32(6):1197-203.
PMID: 24916771
Background: This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), and antitumor activity of PX-866, a phosphatidylinositol 3-kinase inhibitor, combined with cetuximab in...
8.
Senestraro S, Crowe J, Vo A, Covell Jr D, Ferracane J, Wang M, et al.
J Am Dent Assoc
. 2013 Nov;
144(12):1334.
PMID: 24282259
No abstract available.
9.
Senestraro S, Crowe J, Wang M, Vo A, Huang G, Ferracane J, et al.
J Am Dent Assoc
. 2013 Aug;
144(9):997-1005.
PMID: 23989837
Background: The authors conducted a randomized, single-masked clinical trial involving patients who had completed orthodontic treatment to assess changes in the appearance of white-spot lesions (WSLs) that were treated with...
10.
Palmer E, Vo A, Hiles S, Peirano P, Chaudhry S, Trevor A, et al.
J Oral Microbiol
. 2012 Dec;
4.
PMID: 23248741
Background: Genotypic strains of cariogenic mutans streptococci (MS) may vary in important virulence properties. In previous published studies, we identified 39 MS strains from pediatric patients undergoing full-mouth dental rehabilitation,...